Falk R E, Hardy M, Makowka L, Teodorczyk-Injeyan J, Falk J A
J Clin Invest. 1982 Sep;70(3):558-67. doi: 10.1172/jci110648.
This report describes a novel method of immunochemotherapy; the active immunization to the drug 5-fluorouracil (5-FU) with enhanced antitumor activity resulting from its subsequent systemic administration. Two metastasizing carcinomas in the Fischer strain (F344) rat have been used: a chemically induced bladder carcinoma (FBCa) and a spontaneous mammary adenocarcinoma (MACa). Both tumors grow rapidly and result in 100% mortality within 10 wk of implantation. Neither tumor is sensitive to systemic 5-FU alone. Intradermal sensitization to 5-FU before FBCa tumor implantation, followed by 5-FU administered systemically, resulted in significant tumor regression and improvement in survival with eradication of all tumor and cure in 20% of animals. A similar antitumor effect was observed with the MACa. A comparable drug effect was observed when methotrexate sensitization was given before FBCa implantation followed by systemic MTX. Specificity to the sensitizing drug was demonstrated by the lack of effect of sensitization with either 5-FU or MTX unless followed by systemic therapy with the requisite sensitizing agent. Sensitization to 5-FU has also been assessed after FBCa implantation followed by resection of the local tumor. Resection was performed after distant tumor metastases had occurred, and was followed by systemic 5-FU therapy. Whereas tumor resection alone failed to cure any animal, sensitization to 5-FU increased cure rate fourfold over animals receiving systemic 5-FU alone. Antibody to 5-FU in the sera of sensitized animals has been suggested by an immunoenzymatic staining technique and its specificity confirmed in a radioimmunoassay. It is postulated that a combination of the systemic agent and the antibody elicited to it by sensitization produces the significant antitumor effect observed. The antitumor effect observed with this new approach to immunochemotherapy warrants further experimental and clinical study.
本报告描述了一种新型免疫化学疗法;用药物5-氟尿嘧啶(5-FU)进行主动免疫,随后全身给药可增强抗肿瘤活性。使用了Fischer品系(F344)大鼠的两种转移性癌:化学诱导的膀胱癌(FBCa)和自发性乳腺腺癌(MACa)。两种肿瘤生长迅速,植入后10周内死亡率达100%。两种肿瘤单独对全身5-FU均不敏感。在FBCa肿瘤植入前对5-FU进行皮内致敏,随后全身给予5-FU,导致肿瘤显著消退,生存率提高,所有肿瘤被根除,20%的动物治愈。MACa也观察到类似的抗肿瘤作用。在FBCa植入前给予甲氨蝶呤致敏,随后全身给予MTX,观察到类似的药物效果。5-FU或MTX致敏若无随后用相应致敏剂进行全身治疗则无效果,证明了对致敏药物的特异性。在FBCa植入后切除局部肿瘤,然后评估对5-FU的致敏情况。在远处肿瘤转移发生后进行切除,随后进行全身5-FU治疗。单独肿瘤切除未能治愈任何动物,而对5-FU致敏使治愈率比单独接受全身5-FU治疗的动物提高了四倍。免疫酶染色技术提示致敏动物血清中存在5-FU抗体,放射免疫测定证实了其特异性。据推测,全身药物与致敏产生的针对它的抗体相结合产生了观察到的显著抗肿瘤作用。这种免疫化学疗法新方法观察到的抗肿瘤作用值得进一步进行实验和临床研究。